Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07600476
PHASE1

A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors

Sponsor: Kupando GmbH

View on ClinicalTrials.gov

Summary

The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

21

Start Date

2026-07-03

Completion Date

2028-12

Last Updated

2026-08-12

Healthy Volunteers

No

Interventions

DRUG

KUP-101A

Intravenous infusion of KUP-101A

Locations (3)

Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Dermatologie und Allergologie

Munich, Bavaria, Germany

Universitätsklinikum Würzburg

Würzburg, Bavaria, Germany

Fachklinik Hornheide

Münster, North Rhine-Westphalia, Germany